Virax Biolabs Group Limited (VRAX) announced on Wednesday that it has signed a distribution agreement with Europa Biosite to market its immune profiling solutions, ImmuneSelect, in the United Kingdom and Ireland. Following this news, shares of the company saw an increase of over 20% in pre-market trading.
"We anticipate that this collaboration will significantly broaden our commercial presence in the UK and Ireland, thus providing researchers and pharmaceutical organizations with access to ImmuneSelect. This will aid in deepening their understanding of T cell responses and immune status," stated James Foster, CEO of Virax Biolabs.
On the previous day, Virax's stock concluded at $1.68, marking a 3.07% rise. Over the past year, the stock has fluctuated between $0.60 and $9.00.
